Capsaicin, the compound that makes chili peppers hot, is sold as a capsule, a skin cream, and a prescription patch for nerve pain. Applied to the skin or nose, the evidence is solid for nerve pain, joint pain, and a chronic runny nose. Taken orally, changes in weight, waist size and blood fats are small and inconsistent; the link to longer life comes from observation rather than experiment. (Full Review)

Protocol

Standardized capsule approach

100–200 mg extract, 2–4 mg capsaicinoids

Once daily after breakfast, for 12 weeks or longer

Topical over-the-counter approach

0.025–0.075% cream

Applied to the painful area three to four times daily for at least 4 weeks before judging response

Prescription patch approach

Single 60-minute clinic application

After anesthetic pre-treatment; repeatable no sooner than 12 weeks

Time to effect

Patch analgesia

1–2 weeks

Peaks between weeks 2 and 8; low-concentration creams burn most in the first week

Thermogenic and appetite effects

Within a single dose

Appetite suppression appears partly inseparable from gastrointestinal discomfort

Body-composition and lipid changes

12 weeks or more

The shortest interval at which trials detected lipid or body-composition change

Benefits

High: Topical pain relief in neuropathic and osteoarthritis pain; symptom relief in non-allergic rhinitis; enhanced muscular endurance; improved swallowing function in oropharyngeal dysphagia

Medium: Lower all-cause and cardiovascular mortality with habitual chili intake; reduced appetite and short-term energy intake

Low: Increased resting energy expenditure and fat oxidation; modest body-weight and waist-circumference reduction; improved blood lipid profile

Speculative: Brown adipose tissue mass expansion; receptor-mediated extension of healthy lifespan

Contraindications

Active peptic ulcer disease or erosive esophagitis (Los Angeles grade C or D; oral forms)

Inflammatory bowel disease in active flare (oral forms)

Uncontrolled hypertension at or above 160/100 mmHg or myocardial infarction within 90 days (patch)

Child-Pugh Class B or C liver impairment (oral forms)

Pregnancy and lactation (oral supplements)

Broken, irritated, or infected skin at the application site (topical forms)

Documented hypersensitivity to capsaicinoids or Capsicum species

Key Interactions

ACE inhibitors (lisinopril, ramipril, enalapril)

Aspirin and other NSAIDs (ibuprofen, naproxen, diclofenac)

Anticoagulants and antiplatelet agents (warfarin, clopidogrel, apixaban)

Theophylline

Piperine-containing supplements (black pepper extract, BioPerine)

Additive thermogenic supplements (caffeine, green tea catechins, synephrine, yohimbine)

Additive blood-pressure and lipid-lowering supplements (garlic, fish oil, berberine, red yeast rice)

Cold exposure and other brown-fat interventions

Risk & Side Effects

High: Application-site burning, redness, and pain; gastrointestinal burning, abdominal pain, and diarrhea; mucous-membrane irritation of nose, eyes, and airway

Medium: Transient blood-pressure rise during patch treatment

Low: Increased upper-gastrointestinal cancer risk at high habitual intake; reduced protective heat and pain sensation after repeated patch use

Speculative: Reactive metabolite formation and liver stress; acute cardiovascular events after extreme single doses

Monitoring

Marker	Target	Why
Waist circumference	Under 90 cm in men, under 80 cm in women	Most responsive body-composition measure in trials
Fasting triglycerides	50–90 mg/dL	Largest and most reproducible capsaicin lipid effect
Total cholesterol	160–200 mg/dL	Second lipid endpoint that moved, though not robustly
HbA1c	4.8–5.3%	Confirms the null glycemic finding holds individually
Seated blood pressure	110–120 / 70–80 mmHg	No pooled effect, so change signals another cause
hs-CRP	Under 0.55 mg/L in men, under 1.0 mg/L in women	Inflammation route proposed to mediate the mortality link
ALT	10–26 U/L in men, 8–22 U/L in women	Theoretical liver burden from reactive metabolites

Cadence: Baseline panel before starting; symptom review at 2 weeks during titration; full panel at 12 weeks; then every 6–12 months for anyone continuing indefinitely. Topical and patch users need no laboratory monitoring beyond blood pressure around each application.

Qualitative Assessment

Gastrointestinal comfort — burning, cramping, stool frequency and urgency during titration
Reflux symptoms, particularly at night and after evening meals
Appetite and fullness ratings before the next meal
Perceived exertion and repetitions completed during resistance training sessions
Pain intensity and sleep interruption for those using topical or patch formulations
Cold tolerance and subjective warmth, a crude proxy for thermogenic response

Capsaicin for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment